8-K/A: Aditxt Amends Merger Agreement with Evofem, Provides Financials and Pro Forma Statements

Sentiment:

8-K/A Filing (Amendment to Current Report) 25 March 2025 8:57 AM

Aditxt, Inc. files an amendment to its merger agreement with Evofem Biosciences, Inc., including audited financial statements for Evofem and pro forma consolidated financial statements reflecting the acquisitions of Evofem and Appili Therapeutics Inc.

Delay expectedThe Fifth Amendment to the Amended and Restated Merger Agreement includes changing the required consummation date to September 30, 2025, indicating a delay in the merger's completion.

Capital raiseThe document mentions a Parent Investment of $1,500,000 to be completed by April 7, 2025.The consideration for acquiring Evofem includes the issuance or exchange of convertible preferred stock of $91,601,000.

Worse than expectedEvofem's net loss of $(8,860,000) in 2024 is significantly worse than the net income of $52,979,000 in 2023.The pro forma consolidated statement of earnings shows a net loss of $(48,255,000) for the combined entity, indicating a worsening financial situation.

Summary

Aditxt, Inc. has filed an amendment to its merger agreement with Evofem Biosciences, Inc.
The amendment includes audited consolidated financial statements for Evofem as of and for the years ended December 31, 2024 and 2023.
It also includes unaudited pro forma consolidated financial statements as of and for the year ended December 31, 2024, giving effect to the acquisitions of Evofem and Appili Therapeutics Inc.
The Fifth Amendment to the Amended and Restated Merger Agreement includes changing the required consummation date to September 30, 2025, adding a Parent Investment of $1,500,000 to be completed by April 7, 2025, and adding a special meeting consummation date being on or prior to September 26, 2025.
Evofem's net product sales for 2024 were $19,363,000, compared to $18,218,000 in 2023.
Evofem's net loss for 2024 was $(8,860,000), compared to net income of $52,979,000 in 2023.
The pro forma consolidated statement of financial position shows total assets of $196,815,000 and total liabilities of $79,918,000.
The pro forma consolidated statement of earnings shows a net loss of $(48,255,000) for the year ended December 31, 2024.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there's some positive revenue growth for Evofem, the significant net loss and the pro forma consolidated net loss, combined with the going concern uncertainty and the default notice, weigh heavily on the sentiment. The delay in the merger consummation adds to the negative outlook.

Positives

Evofem's net product sales increased from $18,218,000 in 2023 to $19,363,000 in 2024.

Negatives

Evofem experienced a net loss of $(8,860,000) in 2024, a significant downturn from the $52,979,000 net income in 2023.
The pro forma consolidated statement of earnings shows a net loss of $(48,255,000) for the combined entity.

Risks

Evofem has a working capital deficit of $66.8 million and an accumulated deficit of $897.7 million as of December 31, 2024.
Evofem's liquidity resources as of December 31, 2024, were not sufficient to maintain its cash flow needs for the next twelve months.
There is substantial doubt about Evofem's ability to continue as a going concern.
Evofem is contesting a Notice of Event of Default from Future Pak, LLC, which could accelerate repayment of the outstanding principal balance.
Evofem failed to meet the terms of a settlement agreement with TherapeuticsMD, leading to ongoing resolution efforts.

Future Outlook

The document includes forward-looking statements regarding the consummation of the merger, future financial performance, and strategic development plans. However, it also notes significant uncertainties and risks that could materially affect the company's ability to execute its plans.

Industry Context

The announcement reflects ongoing consolidation trends in the biopharmaceutical industry, with Aditxt seeking to expand its portfolio through strategic acquisitions. The focus on women's sexual and reproductive health aligns with a growing market demand for innovative and differentiated products in this sector.

Comparison to Industry Standards

It's difficult to directly compare Evofem's results to industry standards without knowing the specific benchmarks for companies focused on women's sexual and reproductive health.
However, companies like Organon & Co. (MRK) and TherapeuticsMD (TXMD) operate in similar spaces.
Organon, a spin-off from Merck, focuses on women's health and has a broader portfolio, making a direct comparison challenging.
TherapeuticsMD, which also focused on women's health, faced financial difficulties and was acquired, highlighting the risks in this sector.
Evofem's reliance on PHEXXI and SOLOSEC makes it vulnerable to market competition and regulatory changes.
The pro forma statements suggest that the combined entity will face significant financial challenges, requiring careful management and strategic execution.

Legal Proceedings

Evofem is contesting a Notice of Event of Default from Future Pak, LLC.
Evofem is working with TherapeuticsMD on resolution of a settlement agreement.

Stakeholder Impact

Shareholders face uncertainty due to the company's financial difficulties and the potential for dilution.
Employees may be affected by potential cost reductions or restructuring.
Customers may be impacted by changes in product availability or pricing.
Suppliers and creditors face increased risk of non-payment.

Next Steps

Aditxt needs to complete the $1,500,000 investment in Evofem by April 7, 2025.
Evofem needs to hold the Company Shareholders Meeting no later than September 26, 2025.
The parties need to consummate the merger by September 30, 2025.
Evofem needs to resolve the Notice of Event of Default from Future Pak, LLC.
Evofem needs to resolve the settlement agreement with TherapeuticsMD.

Key Dates

Date	Description
2020-04-23	Evofem entered into a Securities Purchase and Security Agreement with Baker Bros. Advisors LP.
2020-05-22	PHEXXI approved by the U.S. Food and Drug Administration (FDA).
2020-09	Evofem commercially launched PHEXXI.
2023-12-11	Aditxt entered into an Agreement and Plan of Merger with Evofem Biosciences, Inc.
2024-07-12	Aditxt completed the Initial Parent Equity Investment and entered into a Securities Purchase Agreement with Evofem.
2024-07-14	Evofem acquired global rights to SOLOSEC.
2024-09-27	Future Pak, LLC provided a Notice of Event of Default and Reservation of Rights relating to the Securities Purchase and Security Agreement dated April 23, 2020.
2024-11	Evofem relaunched the SOLOSEC brand.
2025-03-22	Evofem, Aditxt and Merger Sub entered into the Fifth Amendment to the Amended and Restated Merger Agreement.
2025-04-06	Deadline for Evofem to regain compliance with the Minimum Bid Price Requirement for continued listing on the OTCQB.
2025-04-07	Deadline for Aditxt to complete a $1,500,000 investment in Evofem.
2025-09-26	Special meeting consummation date being on or prior to September 26, 2025.
2025-09-30	Required consummation date for the merger.

Keywords

merger, acquisition, financial statements, pro forma, Evofem, Aditxt, Appili, SOLOSEC, PHEXXI, debt, convertible notes

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.